T-cell lymphoblastic lymphoma/leukemia
Conditions
Interventions
Observation group:NA
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) The initial diagnosis was made between January 1, 2013 and March 1, 2026; 2) Patient age >= 14 years old, gender not limited; 3) Confirmed by pathology or myeloid flow cytometry as T-LBL/ALL; 4) The patient's medical records are complete, including diagnostic information, treatment history, and follow-up data; 5) There are tumor tissues from remaining patients tested in the hospital, such as marrow, peripheral tissue, pathological puncture/biopsy tissue, pathological paraffin cut tissue, and extracted DNA or RNA;
Exclusion criteria
Exclusion criteria: 1) Chemotherapy frequency <= 2 times and efficacy has not been evaluated; 2) Malignant tumors other than AML within the first 5 years of screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, and thyroid cancer after radical surgery; 3) Patients with dysfunction of important organs (heart, brain, ducts, lungs) and previous (within 3 months) gastrointestinal motility disorders; Individuals with a history of uncontrolled high blood pressure, high blood pressure crisis, or high blood pressure encephalopathy, and a history or evidence of significant cardiovascular risk, including any of the following conditions: congestive heart failure, unstable angina, clinically significant arrhythmia (such as ventricular fibrillation, ventricular tachycardia, etc.); History of arterial thrombosis within the past 3 months (such as stroke, transient ischemic attack); Within the past six months, there has been a history of symptomatic deep vein thrombosis, pulmonary embolism, or coronary artery formation surgery, defibrillation, or any clinically related complications or diseases that may pose a risk to the safety of the subjects or interfere with the evaluation, procedures, or completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Countries
China
Contacts
Public Contactsongxianmin
Shanghai General Hospital
Outcome results
None listed